PEBP1 and cervical cancer: To explore the mechanisms by which RKIP induces resistance to cisplatin in cervical cancer cell lines, we exposed HeLa cells to increasing concentrations of cisplatin during 24 hours (Fig. 5C), and found that cisplatin treatment induced ERK activation in both cell lines, more evident for higher doses, but shRKIP transfected cells were more resistant to cisplatin induced PARP and capase-9 cleavage (Fig. 5C).